Skip to content

The research on the objective evaluation of the treatment for melasma by RCM observation on the theory of "promoting blood circulation and removing stasis"

The research on the objective evaluation of the treatment for melasma by RCM observation on the theory of "promoting blood circulation and removing stasis"

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300076869
Enrollment
Unknown
Registered
2023-10-23
Start date
2022-01-01
Completion date
Unknown
Last updated
2023-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melasma

Interventions

Experimental Group:Chinese herbal mask "QubanPowder"
Control Group:Qian Bai hydroquinone cream

Sponsors

Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.In line with the diagnostic criteria for melasma: the skin lesions presented as light brown to dark brown patches on the face, usually symmetrical distribution, without inflammatory manifestations and scales. It occurs mainly in females, after puberty. The disease is severe in summer and mild in winter. Pigmentation after inflammation, nevus fuscocaeruleus zygomaticus, Riehl melanosis and pigmented lichen planus are excluded. 2.Age between 18 and 60, female. 3.Sign informed consent, voluntarily and agree to complete all steps of the clinical study.

Exclusion criteria

Exclusion criteria: 1.Pregnant or lactating women. 2.Patients allergic to the drugs used in this study. 3.Lesions associated with inflammatory or infectious skin diseases. 4.Patients with severe endocrine, gynecological, cardiovascular and cerebrovascular diseases and abnormal liver and kidney function. 5.Patients who have received laser therapy, oral or topical freckle removal drugs within the last 3 months. 6.Patients who have received retinoids within the last 6 months. 7.Patients who can not achieve sun protection as required during treatment.

Design outcomes

Primary

MeasureTime frame
Modified Melasma Area and Severity Index;RCM score;

Secondary

MeasureTime frame
Melasma Quality of Life Scale;Patient Global Assessment;

Countries

China

Contacts

Public ContactXiao Meng

Guang'anmen Hospital, China Academy of Chinese Medical Sciences

mengxiao425@163.com+86 189 1118 0799

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026